Investor · 2 deals

Proto Axiom

biomedical technology incubator

Sydney, NSW

Disclosed deals

Every published round Proto Axiom took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.

Company	Stage	Announced	Amount	Role	Alongside	Sources
AdvanCell	Series D+	15 Jul 2026	$450m	Participant	Ally Bridge Group Alpha Wave Bain Capital Life Sciences Fidelity T. Rowe Price Qatar Investment Authority (QIA)Eli Lilly Sanofi Ventures Brandon Capital Fidelity Management & Research Company Eventide Asset Management Velosity Capital Morningside Eli Lilly and Company SV Health Investors Abingworth SymBiosis Tenmile Piper Heartland Catalio Capital Management Time BioVentures	Forbes Australia (3 Sep 2026), Forbes Australia (16 Jul 2026), Brandon Capital, advancell.com.au, Brandon Capital portfolio, Brandon Capital portfolio, Tenmile portfolio
JumpStart Fertility	Unnamed stage	2025	$4m	Lead	VU Venture Partners	Forbes Australia

Portfolio

Companies Proto Axiom has backed in a published round, and companies whose existing shares it bought off another holder.

Company	What it does	First invested	Rounds	Led
AdvanCell	Produces radiopharmaceuticals that target cancer cells without the typical collateral dam…	15 Jul 2026, Series D+	1	0
JumpStart Fertility		2025	1	1

Funds

Fund closes reported for Proto Axiom, as distinct from the investments it has made.

Fund	Announced	Committed	Target	Close	Sources
No fund closes recorded for Proto Axiom yet.

Portfolio companies acquired

Companies Proto Axiom has backed that another company then bought. An exit for the holding, not a deal Proto Axiom did.

Company	Bought by	Kind	Announced	Price
No portfolio company of Proto Axiom is recorded as having been acquired.

Name	Role	Sources
Anthony Liveris	CEO	Forbes Australia

Coverage

Stories naming Proto Axiom. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

12 deals

Brandon Capital's $60m taypayer-funded biotech bets

Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.

Also australiatimes.com

Unnamed stage $4m

Birth rates are plummeting globally — this Australian IVF trial wants to change that

Proto Axiom has put $4 million into Sydney IVF biotech JumpStart Fertility, a UNSW spin-out, to pay for human trials of a treatment aimed at age-related fertility decline.

Forbes Australia 3 Jul 2025 JumpStart Fertility University of Queensland UNSW Proto Axiom Anthony Liveris Dr Lindsay Wu

Funding announcement

FUNDED April 2023

Techboard's monthly roundup counts 40 Australian startup raises worth $498m in April 2023, headlined by Saluda Medical and Eucalyptus, plus smaller rounds and fund closes by Purpose Ventures and Proto Axiom.

Something wrong? Tell us